R/R AML has a larger FLT3 allelic burden or oncogenic modifications, as opposed to its newly diagnosed counterpart and increased dependence on the FLT3-ITD phenotype.142 So design of treatment schemas for AML patients with FLT3 mutations that incorporate FLT3 inhibitors depends on many factors of their disease. Here, FLT3 is linked to acute myeloid leukemia.